Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Section 5 of 6

Economic information and modeling report

20 evidence topics · 21 sources

Modeling overview

Summary

  • AD109 has no published price, and no cost-effectiveness or budget impact analysis of AD109 was identified.
  • Company market sizing: the prospectus estimates approximately 80 million people with OSA in the United States aged 30 to 69 years, from a study Apnimed commissioned from Clarivate, and approximately one billion worldwide (WHO). The published Apnimed- and Clarivate-authored estimate (Sönmez et al. 2025) is 83.7 million U.S. adults aged 20 years and older in 2024, with OSA defined as an AHI4 of 5 or more events/hr (52% mild, 30% moderate, 18% severe). The two sources state different age bands. The prospectus also cites approximately 3 million new diagnoses per year (Komodo claims), approximately 23 million unique patients with an OSA diagnosis active in the healthcare system from 2019 to 2024 (IQVIA claims), and approximately 10.5 million diagnosed but untreated people. The last figure comes from an Inspire-supported National Sleep Foundation survey of 1,015 adults with self-reported diagnosis, in which approximately 31% of those diagnosed were not receiving treatment.
  • Company payer research reports that payers perceive PAP non-compliance at greater than 60%; Apnimed's planned health economics and outcomes research may include real-world analyses of adherence, healthcare utilization, functional outcomes, and nocturnal oxygenation.
  • Published cost-effectiveness of OSA treatments: CPAP for moderate to severe OSA had an ICER of $15,915 per QALY gained over a lifetime horizon in a Markov model (Pietzsch et al. 2011), and ICERs of $3354 (third-party payer) and $314 (societal) per QALY gained (Ayas et al. 2006). In another analysis, CPAP cost $12,495 per DALY averted from the health care system perspective and was dominant from the societal perspective (Streatfeild et al. 2019). A meta-analysis of 15 studies (34 in the systematic review) found CPAP cost-effective against other treatments collectively, against no treatment, and against oral appliances, with low certainty (Sajith Kumar et al. 2025). Hypoglossal nerve stimulation increased lifetime costs by $42,953 with an ICER of $39,471/QALY in a 5-state Markov model (Pietzsch et al. 2015). Published obesity models include OSA as a modeled outcome or complication (ICER 2025; Hoog et al. 2025; Annemans et al. 2026).
  • Payer coverage of OSA treatments: Medicare initially limits CPAP coverage to a 12-week period and continues it only for beneficiaries who benefit (NCD 240.4). CMS states that beneficiaries prescribed Zepbound for moderate to severe OSA in adults with obesity should continue to receive Medicare Part D coverage, subject to the plan's utilization management requirements. An Aetna prior authorization policy for tirzepatide in OSA sets an initial authorization of 6 months and a continuation of 12 months, with continuation requiring a positive response. ICER reports that coverage was easier to obtain when a comorbidity was on the FDA label.

Product-specific economic evaluation of AD109

No evidence found.

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

Summary

No budget impact model of AD109 was identified, and AD109 has no published price. The report holds evidence for these inputs of a future model:

  • Eligible population: approximately 80 million U.S. people aged 30 to 69 years (prospectus) or 83.7 million U.S. adults aged 20 years and older with an AHI4 of 5 or more (Sönmez et al. 2025); approximately 23 million diagnosed patients active from 2019 to 2024, approximately 3 million new diagnoses per year, and approximately 10.5 million diagnosed but untreated (prospectus, from a National Sleep Foundation survey of 1,015 adults); and, for a PAP-intolerant or refusing population, the SynAIRgy intent-to-treat split of 411 (66.8%) with PAP intolerance and 205 (33.3%) with PAP refusal.
  • Comparator and care costs: average costs of $2,105 per year for testing, appointments, treatment devices, and surgery if necessary (Frost & Sullivan 2016); payer costs per subject of $1,840 for a laboratory-based and $1,575 for a home-based diagnostic pathway (Kim et al. 2015); and an incremental lifetime cost of $42,953 for hypoglossal nerve stimulation (Pietzsch et al. 2015). The report quotes no acquisition price for tirzepatide.
  • Discontinuation: across the two phase 3 trials combined, overall treatment discontinuation by Week 26 was 35.2% (227) with AD109 and 15.5% (100) with placebo, and treatment discontinuation due to treatment-emergent adverse events by Week 26 was 25.0% (163/653) and 6.7% (43/646); in the LunAIRo main cohort, overall discontinuation at month 12 was 46.5% with AD109 and 25.1% with placebo. For CPAP, termination (cessation of reimbursements) was 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years among 480,000 people (Pépin et al. 2021).